Safety and Efficacy of Remimazolam in OPCAB Surgery

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam is a novel short-acting benzodiazepine drug that acts on the benzodiazepine binding site of gamma-aminobutryic acid (GABA) A receptor, is metabolized by esterase, and has a context-sensitive half-time of about 6-7 minutes. Looking at some previous studies using Remimazolam, the safety and efficacy as a general anesthetic have been sufficiently proven.

In particular, compared to intravenous anesthetic agents such as propofol, the action time of anesthetics is relatively longer, but the frequency of hypotension is low. However, most studies have been conducted on patients of American Society Anesthesiologist (ASA) class I-II, and studies on patients with high severity have not yet been sufficiently secured.

Therefore, this study aims to compare the efficacy and safety of Remimazolam as an anesthetic with Sevoflurane in terms of hemodynamics in patients with high severity undergoing OPCAB surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ajou University School of Medicine
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

• Adult patients 19 years of age or older to receive OPCAB surgery

• Clinical diagnosis of coronary artery obstructive disease

Exclusion Criteria:

• Ejection fraction < 35% at preoperative ECHO test

• Mitral regurgitation > grade 2 at preoperative ECHO test

• Currently using inotropics

• Currently receiving mechanical support